Hansa Biopharma AB

HNSA · Nasdaq Stockholm · Healthcare

33.18SEK −2.8%last day

Price as of 2 October 2026

The price over the past year, with dividends: −15.9%

Performance

1 month

−25.4%

1 year

−15.9%

3 years, per year

−2.0%

5 years, per year

−22.4%

Largest fall, 3 years

−92.3%

Below the peak now

−90.5%

Volatility, 1 year

66.2%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

−6.9

Dividend yield

0.0%

Return on equity

−148.0%

Net margin

–

Market value

336 m USD

Quality, value and trend

Where Hansa Biopharma stands against every Nordic stock today. 100 is best.

Quality13

Profitability and a sound balance sheet over time. Better than 13% of Nordic stocks.

Value2

The price measured against earnings, assets and cash flow. Better than 2% of Nordic stocks.

Trend54

The price development over the past year. Better than 54% of Nordic stocks.

Combined7

Quality, value and trend together. Better than 7% of Nordic stocks.

About Hansa Biopharma

Hansa Biopharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 130 employees.

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis